title: Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.
abstract: Impairment of fibrinolytic function plays an important role in the mechanism of thrombotic disorders in cancer patients. This study assessed the circulating level of thrombin-activatable fibrinolysis inhibitor in patients with lung cancer and its expression by several lung cancer cell lines. The plasma concentrations of thrombin-activatable fibrinolysis inhibitor were significantly increased in lung cancer patients compared to healthy subjects. The concentration of thrombin-activatable fibrinolysis inhibitor was particularly higher in patients with small cell carcinoma compared to those with adenocarcinoma or squamous cell carcinoma, and in cancer patients that responded to chemotherapy compared to non-responders. In vitro studies showed more expression of thrombin-activatable fibrinolysis inhibitor in small cell carcinoma than in adenocarcinoma cell lines and more expression in lung cancer cell lines sensitive to anti-cancer agents than in resistant cell lines. This study suggests that thrombin-activatable fibrinolysis inhibitor, in part secreted from lung cancer cells, may play a role in the pathogenesis of thrombotic disorders in lung cancer patients.
authors.affiliation: Third Department of Internal Medicine, Respiratory Division, Mie University School of Medicine, Edobashi 2-174, Tsu City, Mie 514-8507, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Hataji
authors.forename: Osamu
authors.initials: O
authors.lastname: Taguchi
authors.forename: Esteban Cesar
authors.initials: EC
authors.lastname: Gabazza
authors.forename: Hisamichi
authors.initials: H
authors.lastname: Yuda
authors.forename: C N
authors.initials: CN
authors.lastname: D'Alessandro-Gabazza
authors.forename: Hajime
authors.initials: H
authors.lastname: Fujimoto
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nishii
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Hayashi
authors.forename: Koji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Adachi
mesh_terms: D000230:Adenocarcinoma / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology; D025901:Carboxypeptidase B2 / Q000097:blood* / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood; D018288:Carcinoma, Small Cell / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood; D019008:Drug Resistance, Neoplasm; D005260:Female; D015870:Gene Expression; D006801:Humans; D008099:Liver / Q000378:metabolism; D008175:Lung Neoplasms / Q000097:blood*; D008297:Male; D008875:Middle Aged; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D025901:Carboxypeptidase B2